Board Committees

Paul A. Gendron joined the board in May 2019 after serving as a financial consultant to the Company; assisting with accounting, internal control and financial reporting matters. Upon joining the board, Mr. Gendron was appointed Chairman of the Audit Committee and also serves on the Compensation Committee.

With more than 30 years of experience, Mr. Gendron previously was a client service partner with PricewaterhouseCoopers LLP where he held various leadership roles serving global public and private multibillion-dollar corporations. Leadership assignments included North Texas Market Assurance Leader from 2009 until 2014, U.S. Assurance Talent Transformation Leader from 2014 until 2016, and Southwest Region Technology Practice Risk Management Leader. In his market assurance leadership role, Mr. Gendron led the Assurance practice in the Dallas, Fort Worth, Austin and Little Rock offices; providing services in internal and external audit, risk and information technology assurance, and accounting and capital markets advisory. His areas of strength include board governance, project management, risk management, executive management, public offerings, and mergers and acquisitions.

Mr. Gendron is a CPA and holds a Bachelor of Business Administration in Accounting degree from the University of Texas at Austin. He has served on non-profit boards during his career as well as the Accounting Advisory Council at the University of Texas at Austin. 

Kenneth D. Eichenbaum, M.D., M.S.E., joined the InfuSystem Board of Directors in May 2024 and serves on the Audit Committee and Nominating and Governance Committee. 

Dr. Eichenbaum is a board-certified anesthesiologist who has practiced clinically at Corewell Health William Beaumont University Hospital since 2017 and Trinity Health Oakland Hospital since 2021. He has extensive experience working with infusion pumps and related technologies for the delivery of critical care and pain management therapies. Dr. Eichenbaum has a strong business background in evaluating biotech and med-tech companies and has 20 years of experience working with investment firms. He also lectures in hospital business management and advises Accountable Care Organizations.

Dr. Eichenbaum graduated from the Icahn School of Medicine at Mount Sinai in New York and completed a Fellowship in Cardiothoracic Anesthesia at Stanford University Medical Center. He holds a Master of Science in data network engineering and a Bachelor of Science in materials science engineering from the University of Pennsylvania. Dr. Eichenbaum also holds a bachelor’s degree from the Wharton School with a concentration in finance.

Beverly A. Huss joined the InfuSystem Board of Directors in May 2024, where she serves on the Audit Committee and as co-chair of the Compensation Committee.

Huss brings extensive medical devices and medical services experience to the board, including business operations, management and corporate governance. She is a former chief executive officer with more than 25 years of management experience in the medical device industry and a current and former member of several public and private company boards over two decades. 

Huss served as the CEO of Pagonia Medical, Inc., a private medical device company focused on the preservation of tissue following a heart attack, stroke, traumatic brain injury and other medical conditions and as the President and CEO of Qool Therapeutics, Inc., which focused on temperature management therapies. Prior to joining Qool, Huss was President and CEO at a start-up medical device company, Vibrynt, Inc., and held multiple senior-level leadership positions at Guidant Corporation, including President, Endovascular Solutions, Vice President, Global Marketing, Vascular Intervention, and Vice President of the Stent Business Unit.

Huss currently serves on the board of directors of publicly traded Accuray Incorporated, an oncology company (chair of the compensation committee), Iridex Inc., an ophthalmology laser company (chair of the compensation committee), and Vicarious Surgical Inc., a robotics company developing technology focused on abdominal access and visualization through a single port. Her prior public company board experience includes Artes Medical, Inc., Coala-Life Group AB, Wright Medical Group N.V. and Dade Behring Holdings, Inc. 

Huss holds a Bachelor of Science in metallurgical engineering from the University of Illinois and a Master of Science in technology management from Pepperdine University.  Huss holds a National Association of Corporate Directors (NACD) Certification.

Ralph Boyd joined InfuSystem’s board of directors in May 2022 and currently serves as chair of the Compensation Committee. He also serves as a member of the Corporate Nominating and Governance Committee.

Boyd has extensive experience as a senior executive and board leader in both the public company and nonprofit sectors and served as a federal prosecutor and assistant attorney general in the U.S. Department of Justice. Boyd currently serves as president and CEO of SOME, Inc., a large Washington, D.C.-based housing development, health care, and human services organization. His executive experience also includes serving as EVP and general counsel of a Fortune 50 financial services company, CEO of a major corporate foundation, CEO of the Americas region of an international real estate development organization, and a regional CEO of The American Red Cross. Boyd also previously practiced law as a partner in the Boston office of Goodwin Procter LLP and the Washington, D.C., office of Alston & Bird.

Boyd previously served as a board member and Audit Committee chair of the DirecTV Group, Inc. (formerly NASDAQ: DTV) and as a member of the company’s Nominating and Governance Committee.

He currently serves as chair of Sandy Spring Bancorp’s (NASDAQ: SASR) Compensation Committee and as a member of the Executive and Nominating and Governance Committees. Boyd also is the non-executive chairman of the NHP Foundation, a nonprofit developer, owner, and operator of multi-family affordable housing properties nationwide.

Boyd is a graduate of Haverford College and Harvard Law School.

Paul A. Gendron joined the board in May 2019 after serving as a financial consultant to the Company; assisting with accounting, internal control and financial reporting matters. Upon joining the board, Mr. Gendron was appointed Chairman of the Audit Committee and also serves on the Compensation Committee.

With more than 30 years of experience, Mr. Gendron previously was a client service partner with PricewaterhouseCoopers LLP where he held various leadership roles serving global public and private multibillion-dollar corporations. Leadership assignments included North Texas Market Assurance Leader from 2009 until 2014, U.S. Assurance Talent Transformation Leader from 2014 until 2016, and Southwest Region Technology Practice Risk Management Leader. In his market assurance leadership role, Mr. Gendron led the Assurance practice in the Dallas, Fort Worth, Austin and Little Rock offices; providing services in internal and external audit, risk and information technology assurance, and accounting and capital markets advisory. His areas of strength include board governance, project management, risk management, executive management, public offerings, and mergers and acquisitions.

Mr. Gendron is a CPA and holds a Bachelor of Business Administration in Accounting degree from the University of Texas at Austin. He has served on non-profit boards during his career as well as the Accounting Advisory Council at the University of Texas at Austin. 

Beverly A. Huss joined the InfuSystem Board of Directors in May 2024, where she serves on the Audit Committee and as co-chair of the Compensation Committee.

Huss brings extensive medical devices and medical services experience to the board, including business operations, management and corporate governance. She is a former chief executive officer with more than 25 years of management experience in the medical device industry and a current and former member of several public and private company boards over two decades. 

Huss served as the CEO of Pagonia Medical, Inc., a private medical device company focused on the preservation of tissue following a heart attack, stroke, traumatic brain injury and other medical conditions and as the President and CEO of Qool Therapeutics, Inc., which focused on temperature management therapies. Prior to joining Qool, Huss was President and CEO at a start-up medical device company, Vibrynt, Inc., and held multiple senior-level leadership positions at Guidant Corporation, including President, Endovascular Solutions, Vice President, Global Marketing, Vascular Intervention, and Vice President of the Stent Business Unit.

Huss currently serves on the board of directors of publicly traded Accuray Incorporated, an oncology company (chair of the compensation committee), Iridex Inc., an ophthalmology laser company (chair of the compensation committee), and Vicarious Surgical Inc., a robotics company developing technology focused on abdominal access and visualization through a single port. Her prior public company board experience includes Artes Medical, Inc., Coala-Life Group AB, Wright Medical Group N.V. and Dade Behring Holdings, Inc. 

Huss holds a Bachelor of Science in metallurgical engineering from the University of Illinois and a Master of Science in technology management from Pepperdine University.  Huss holds a National Association of Corporate Directors (NACD) Certification.

Scott Shuda has been a member of the Company’s Board of Directors since September 2016 and currently serves as the Chair of the Board as well as for the Compensation Committee. Mr. Shuda also serves on the Corporate Nominating Governance Committee. 

Mr. Shuda has extensive experience working with small companies, particularly public microcaps, helping them unlock value and achieve their full potential. His background as a corporate finance attorney, general counsel of a public company, and managing director of private investment funds focusing on healthcare and technology companies, provides InfuSystem with a deep understanding of the challenges facing small public companies, including the perspective of shareholders.

Mr. Shuda is a Managing Director and Co-founder of Meridian OHC Partners, LP and BlueLine Partners, LLC; investment firms that focus on publicly listed technology and healthcare companies. Mr. Shuda served as a director of Iridex Corporation (NASDAQ: IRIX), a global leader in ophthalmic laser systems, from 2012 to 2017 where he chaired Iridex’s Compensation Committee and served as a member of the Nominating and Governance Committee. Mr. Shuda rejoined the Iridex board in April 2019 and serves on the Audit and Compensation Committees. He served as a Director and Audit Committee member of MGC Diagnostics Corporation (formerly Angeion Corporation) (NASDAQ: MGCD), a global respiratory diagnostics company from 2010 to 2011. Prior to co-founding BlueLine Partners in April 2004, Mr. Shuda was General Counsel to Vicinity Corporation, an internet search company that went public in 2000 and was acquired by Microsoft in 2002. Prior to his employment with Vicinity, Mr. Shuda practiced law in California and New York, most recently in the Silicon Valley office of Latham & Watkins LLP. 

Mr. Shuda holds both Juris Doctor and Master of Business Administration degrees from Georgetown University.

Ralph Boyd joined InfuSystem’s board of directors in May 2022 and currently serves as chair of the Compensation Committee. He also serves as a member of the Corporate Nominating and Governance Committee.

Boyd has extensive experience as a senior executive and board leader in both the public company and nonprofit sectors and served as a federal prosecutor and assistant attorney general in the U.S. Department of Justice. Boyd currently serves as president and CEO of SOME, Inc., a large Washington, D.C.-based housing development, health care, and human services organization. His executive experience also includes serving as EVP and general counsel of a Fortune 50 financial services company, CEO of a major corporate foundation, CEO of the Americas region of an international real estate development organization, and a regional CEO of The American Red Cross. Boyd also previously practiced law as a partner in the Boston office of Goodwin Procter LLP and the Washington, D.C., office of Alston & Bird.

Boyd previously served as a board member and Audit Committee chair of the DirecTV Group, Inc. (formerly NASDAQ: DTV) and as a member of the company’s Nominating and Governance Committee.

He currently serves as chair of Sandy Spring Bancorp’s (NASDAQ: SASR) Compensation Committee and as a member of the Executive and Nominating and Governance Committees. Boyd also is the non-executive chairman of the NHP Foundation, a nonprofit developer, owner, and operator of multi-family affordable housing properties nationwide.

Boyd is a graduate of Haverford College and Harvard Law School.

Kenneth D. Eichenbaum, M.D., M.S.E., joined the InfuSystem Board of Directors in May 2024 and serves on the Audit Committee and Nominating and Governance Committee. 

Dr. Eichenbaum is a board-certified anesthesiologist who has practiced clinically at Corewell Health William Beaumont University Hospital since 2017 and Trinity Health Oakland Hospital since 2021. He has extensive experience working with infusion pumps and related technologies for the delivery of critical care and pain management therapies. Dr. Eichenbaum has a strong business background in evaluating biotech and med-tech companies and has 20 years of experience working with investment firms. He also lectures in hospital business management and advises Accountable Care Organizations.

Dr. Eichenbaum graduated from the Icahn School of Medicine at Mount Sinai in New York and completed a Fellowship in Cardiothoracic Anesthesia at Stanford University Medical Center. He holds a Master of Science in data network engineering and a Bachelor of Science in materials science engineering from the University of Pennsylvania. Dr. Eichenbaum also holds a bachelor’s degree from the Wharton School with a concentration in finance.